Eevia Health, a pioneer in sustainable bioactive extracts, is repositioning itself for global growth by relocating its production facility from Finland to the advanced BIOTEP facility in Tromsø, Norway. This strategic move comes after the company faced significant revenue loss in 2023 due to a major U.S. customer reducing its purchases. However, Eevia has since regained commercial traction, engaging with leading nutraceutical brands worldwide.

The decision to move production stems from the need to optimize the valorization of side-streams, which are currently treated as biowaste. By utilizing the state-of-the-art technologies at BIOTEP, Eevia aims to transform these side-streams into valuable nutritional inputs, thus enhancing profitability and sustainability.

Eevia's partnership with Nofima and the BIOTEP facility offers a strategic platform for scaling and innovation, providing access to modern technologies and a unique environment for product development. This collaboration is expected to significantly reduce operational costs and improve production efficiency.

Despite the challenges, Eevia's CEO, Stein Ulve, remains optimistic about the company's future. The partnership with Nofima is seen as a pivotal step towards achieving stable profitability and expanding Eevia's presence in the fast-growing polyphenolic nutraceutical space.

Given the strategic realignment and the potential for growth in the polyphenol-rich extract market, investors might consider holding onto their shares as Eevia navigates through this transition. The company's focus on innovation and cost-efficiency positions it well to compete with larger multinational players, potentially offering substantial returns in the long term.